Travere Therapeutics, Inc.

TVTX Healthcare Biotechnology

Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 48.2%, EPS fell 164.3%, free cash flow grew 604.2% and total debt rose 93.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

49.60 3.19 −6.04%
Market cap
$5.0B
P/E
0.0×
Fwd P/E
196×
Dividend yield
—
F-score
6/9
Altman Z
1.78
Beneish M
−1.74
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 6 6 5

+8 more TTM periods

ROE
(151.79%) (32.57%) (29.38%) (410.76%)
ROA
(6.42%) (3.88%) (4.26%) (16.98%)
ROIC
(18.31%) (24.41%) (37.84%) (43.68%)
Return on Tangible Assets
(9.32%) (7.91%) (9.07%) (36.84%)
Average Days of Receivables
49.77 59.43 59.60 69.50
Free Cash Flow per Share
0.16 (0.31) (0.23) (1.21)
Free Cash Flow
15.16 (28.94) (20.37) (107.87)
Other line items

Show all line items

Columns are period end dates